Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura

ConclusionsFurther work is needed to compare treatment of congenital TTP with PI versus recombinant ADAMTS ‐13. PI may provide longer duration of ADAMTS‐13 effect, but is limited by plasma volume required, whereas recombinant therapy can provide a higher ADAMTS‐13 peak. We propose that investigation of interindividual clearance of ADAMTS‐13 is necessary to optimise treatment, to enable rationale for dose and frequency of prophylaxis.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - Category: Hematology Authors: Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research